Frederick Howard, MD, explored the evolving intersection of artificial intelligence (AI), computational pathology, and precision breast oncology.
|Articles|May 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 5
- Volume 15
- Issue 5
Novartis Seeks Approval for Gleevec in Four Rare Cancers
Novartis Seeks Approval for Gleevec in Four Rare Cancers
Advertisement
EAST HANOVER, New JerseyNovartis has submitted supplemental NDAs for imatinib (Gleevec) as treatment for four rare types of cancer. The diseases, all with Gleevec-sensitive pathways, are dermatofibrosarcoma protuberans, certain forms of myeloproliferative disorders, hypereosinophilic syndrome, and systemic mastocytosis.
Articles in this issue
over 20 years ago
Genentech Files sBLA for Avastin for First-Line NSCLC Treatmentover 20 years ago
RFA Effective for Single, Small Hepatocellular Carcinomaover 20 years ago
New Imaging, ChemoRT Recommendations From NCCNover 20 years ago
Panitumumab Improves PFS in Advanced Colon Caover 20 years ago
Studies Question Watchful Waiting for Some Prostate Ca Ptsover 20 years ago
Growing Evidence Supports Stem Cell Hypothesis of Cancerover 20 years ago
FDA Approves New Every-3-Week Dosing for Aranespover 20 years ago
Telephone Often Delivers News of Breast Cancer Diagnosisover 20 years ago
IND Submitted for CYT-500Advertisement
Related to this article
“Vitamin C is a powerful epigenetic drug, which is not generally realized,” said Peter A. Jones, PhD, DSc (hon).
Findings from the AZUR-1 trial support the FDA approval of dostarlimab for patients with stage II/III locally advanced rectal cancer.
Investigators will share detailed findings from the phase 1a/b EMBOLD PanTumour-101 study at the European Society for Medical Oncology Congress 2026.
The anti–IL-1α antibody vilamakitug added to trifluridine/tipiracil met its prespecified 12-month overall survival threshold in refractory metastatic colorectal cancer.
Long-term QUILT-3.032 data showed a 71% CR rate, with a median duration of 26.6 months with nogapendekin alfa inbakicept/BCG in BCG-unresponsive NMIBC.
The FDA assigned a PDUFA date of June 14, 2027, to UGN-103, for the treatment of recurrent low-grade intermediate-risk non–muscle invasive bladder cancer.
Leah Katz, MD, MPH, discussesed NeoORB data on neoadjuvant radiotherapy and why radiation timing may open new treatment paradigms in breast cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Dostarlimab in Previously Untreated Locally Advanced Rectal Cancer
2
Ris-Rez Produces Anti-Tumor Activity in Extensive-Stage SCLC
3
Is Vitamin C an Epigenetic Interception Strategy in Pre-Leukemic Disease?
4
AI Foundation Models & Molecular Biomarkers in Breast Cancer
5